FDA inspectors visited the Mohali plant in the process of giving approval to Ranbaxy's application for Valsartan.
Adjusted gross revenue of the industry has grown just 5.3 per cent during the financial year ended March 31
Data also show that several other leading domestic pharma companies have recalled their products from the US
It is not without reason that Japanese consumer electronics companies such as Sony, Panasonic, Hitachi, Daikin and Sharp are investing significant sums in India.
To revive the two state-run telecom operators, Bharat Sanchar Nigam Limited (BSNL) and Mahanagar Telephone Nigam Ltd (MTNL), the government is likely to waive the one-time fee these telcos need to pay for retaining additional spectrum.
The National Pharmaceutical Pricing Authority will soon notify prices of as many as 150 packs of essential medicines in line with the new pharma pricing policy, according to official sources.
In a development that could hasten the entry of the generic version of Gleevec into the US market, Indian drug major Sun Pharma has sued Novartis Pharmaceuticals Corp in the District Court of New Jersey, demanding rights to launch a generic version of the cancer drug before the Novartis patent expires.
Last month, the US Food and Drugs Administration had placed Wockhardt's facilities in Waluj near Aurangabad on import alert, barring supply of various products from these facilities to the US.
The complaint was lodged by Mumbai-based Express Industry Council of India, which represented major express courier and cargo companies such as DTDC, Aramex India, Blue Dart, DHL Express, GATI and First Flight.
The German sportswear maker has brought Haskell, who played a key role in writing the growth story for Adidas in China, to give Reebok's India business a 'fresh start' after the alleged Rs 870-crore (Rs 8.7-billion) fraud by former managing director Subhinder Singh Prem and chief operating officer Vishnu Bhagat.
FDA had also issued warning letters to Ranbaxy's Paonta Sahib and Dewas facilities as it found extensive problems and deviations from manufacturing norms.
While the MRP of the device is Rs 37,380, Samsung Galaxy Note II is being sold at much lower prices on e-commerce portals.
There may be shortage of drugs till pharmaceutical companies supply new batches with revised MRPs.
Apollo Pharmacy, the country's largest branded drug retail network with over 1,500 outlets, has temporarily suspended sale of medicines manufactured by Ranbaxy Laboratories. It has also stopped further procurement from the company for now.
Says inordinate delay on this and other issues raised by firm earlier are impacting investor confidence.
The 2008 deal agreement contains provisions of arbitration to be held in that country.
Consultants are working with various teams on manufacturing, R&D, etc, to assess per-month productivity of each department.
The trouble-stricken company has sought appointment with at least two major hospitals -- Mumbai-based Jaslok and Gurgaon-based Medanta Medicity.
The company was indicted for violations at one of its US facilities in 2009, even after Daiichi Sankyo took over as majority shareholder in 2008.
The US FDA, during its inspection of Ranbaxy's manufacturing facilities in India, between 2006 and 2008, had found violations, incomplete testing records and an inadequate stability programme, besides manufacturing practices that did not follow regulations.
© 2025 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances